Intended Audience:
This webcast is designed for all practitioners with the following specialties or subspecialties: Primary Care Physicians, Hypertension Specialists, Internists, Preventive Medicine Specialists, Family Medicine Specialists, Cardiologists, Nurse Practitioners, Physician Assistants, Pharm.D’s, Clinical Pharmacists, and Residents and Fellows
Registration:
Enrollment for this webcast is complimentary, and clinicians are invited to attend this CME-certified webcast and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support:
Supported by an independent educational grant from Forest Pharmaceuticals, Inc.
Accreditation Statement for Jointly-Sponsored Programs:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Faculty and Provider Disclosure:
It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Faculty Disclosures:
Michael Weber, MD
Speaking/Consulting: Boehringer-Ingelheim, Novartis, BMS, Pfizer, Merck, Sanofi-Aventis, Daiichi-
Sankyo, and Forest.
Henry Black, MD
Consulting: Novartis, MSD, Pfizer, BMS, Sanofi-Aventis, Boeringer-Ingelheim, Forrest,
Gilhead, Myogen
Speakers’ Bureau: Novartis, MSD, Pfizer, BMS, Sanofi-Aventis, Boeringer-Ingelheim, Forest
L. Michael Prisant, MD, FACP, FACC, FAHA
Grant/Research: Astra-Zeneca, Abbott, Boerhinger-Ingelheim, Eli-Lilly, NovartisConsultant: Astra-Zeneca, Abbott, CV Therapeutics, Merck, Merck/Schering-Plough, Reliant, Schwarz, SunTech MedicalSpeaker’s Bureau: Astra-Zeneca, Abbott, Boerhinger-Ingelheim, CV Therapeutics, Merck, Merck/Schering-Plough, Reliant
Program Faculty:
Michael Weber, MD
Professor of Medicine
SUNY Downstate College of Medicine
Brooklyn, NY
Henry R. Black, MD
Charles J. And Margaret Roberts Professor of Preventive Medicine
Professor of Internal Medicine
Rush University Medical Center
Chicago, IL
L. Michael Prisant, MD, FACP, FACC, FAHA
Professor of Medicine
Medical College of Georgia
Director, Hypertension and Lipid Clinic
Augusta, GA
Educational Objectives:
•Cardiologists, internists, and hypertension specialists will learn how to approach hypertension as a systematic disease, with multiple manifestations, and associations, including assessment of coexisting conditions that support use of specific classes or agents.
•Clinical specialists will learn about the complications linked to healthcare disparities observed in specific patient populations, and the importance of providing access, treatment, and monitoring of patients with multiple risk CV risk factors.
•Cardiologists and hypertension specialists will learn how to manage complicated patients with high blood pressure, including those with ischemic heart disease and/or heart failure.
•Cardiologists and hypertension specialists will learn the importance of early treatment of patients with high blood pressure, markers to look for, and the importance of treating both systolic and diastolic blood pressure abnormalities.
•Cardiologists and hypertension specialists will learn how to apply the results of landmark clinical trials and national guidelines to their clinical practice.
•Cardiologists and hypertension specialists will learn about the possible role of the new and emerging beta-1 cardioselective beta-blockers and their role in the management of hypertension and related cardiovascular disorders, including heart failure and CVD.
•Cardiologists and hypertension specialists will learn how to apply evidencebased and guideline-consistent management of hypertension to specific patient subgroups. Current clinical studies and trials will be reviewed and discussed in detail.
•Cardiologists and hypertension specialists will learn about the effects of antihypertensive agents, including the effects of beta-1 selective beta blockers on myocardial remodeling, heart failure, endothelial reactivity, the endothelial nitric oxide production and its metabolites on the pathogenesis of essential hypertension, CVD, and platelet activation; and, the possible implications for clinical management.
•Cardiologists and hypertension specialists will learn indications for use of beta-1 selective beta-blockers as initial monotherapy or for combination therapy for treatment of high blood pressure.
•Cardiologists and hypertension specialists will learn what compelling indications, historical features, and/or co-morbid conditions support use of beta-blockers and other agents for management of hypertension.
•Cardiologists and hypertension specialists will learn prescribing strategies that reduce side effects and increase the likelihood of adherence to an antihypertensive drug regimen.
•Cardiologists and hypertension specialists will learn about the safety profiles of antihypertensive agents across multiple patient risk groups.
•Cardiologists and hypertension specialists will learn to recognize markers of target organ damage and learn which antihypertensive agents are useful for preventing end organ complications such as stroke, heart failure, and diabetic renal disease.
|
